Athira Pharma, Inc. ATHA
We take great care to ensure that the data presented and summarized in this overview for Athira Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATHA
View all-
Perceptive Advisors LLC New York, NY5.4MShares$1.51 Million0.06% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.2MShares$896,1860.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.54MShares$430,6150.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$417,9810.49% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$417,9810.02% of portfolio
-
Black Rock Inc. New York, NY676KShares$189,3480.0% of portfolio
-
Tang Capital Management LLC San Diego, CA600KShares$168,0000.01% of portfolio
-
Acadian Asset Management LLC Boston, MA434KShares$121,6570.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ425KShares$119,1370.01% of portfolio
-
Bank Of America Corp Charlotte, NC416KShares$116,5240.0% of portfolio
Latest Institutional Activity in ATHA
Top Purchases
Top Sells
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Insider Transactions at ATHA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Martin Javier San CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,826
-23.2%
|
$0
$0.56 P/Share
|
|
Jan 02
2025
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
8,510
-9.23%
|
$0
$0.56 P/Share
|
|
Jan 02
2025
|
Robert Renninger SVP, Finance and Accounting |
SELL
Open market or private sale
|
Direct |
2,881
-3.11%
|
$0
$0.56 P/Share
|
|
Jan 02
2025
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,510
-6.11%
|
$0
$0.56 P/Share
|
|
Jan 02
2025
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
25,107
-9.38%
|
$0
$0.56 P/Share
|
|
Dec 31
2024
|
Martin Javier San CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
46,667
+50.0%
|
-
|
|
Dec 31
2024
|
Mark Worthington General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,667
+28.44%
|
-
|
|
Dec 31
2024
|
Robert Renninger SVP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
12,359
+11.77%
|
-
|
|
Dec 31
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
36,667
+20.84%
|
-
|
|
Dec 31
2024
|
Mark James Litton President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,333
+28.81%
|
-
|
|
Nov 18
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
3,651
+6.16%
|
$0
$0.55 P/Share
|
|
Nov 18
2024
|
Robert Renninger SVP, Finance and Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
3,651
+4.35%
|
$0
$0.55 P/Share
|
|
Nov 18
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,920
+8.82%
|
$0
$0.55 P/Share
|
|
Sep 05
2024
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
2,525
-10.79%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Andrew Gengos CFO and Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,272
-1.29%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
5,032
-3.06%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,525
-4.64%
|
$0
$0.57 P/Share
|
|
Sep 05
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,525
-2.65%
|
$0
$0.57 P/Share
|
|
Sep 03
2024
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.94%
|
-
|
|
Sep 03
2024
|
Andrew Gengos CFO and Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.82%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 42.4K shares |
|---|---|
| Exercise of conversion of derivative security | 241K shares |
| Grant, award, or other acquisition | 97.2K shares |
| Open market or private sale | 69.7K shares |
|---|